Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Stocks

Biotechs Fall Apart with Dark Cross Neutral Signal

by November 15, 2024
November 15, 2024
Biotechs Fall Apart with Dark Cross Neutral Signal

(This is an excerpt from the subscriber-only DP Weekly Wrap for Friday)

Friday, the Biotechnology ETF (IBB) 20-day EMA crossed down through the 50-day EMA (Dark Cross), above the 200-day EMA, generating an IT Trend Model NEUTRAL Signal. IBB recently switched to a BUY Signal on Friday November 8 and we said at the time, “IBB is approaching the top of a four-month trading range (resistance), so this BUY Signal doesn’t look very juicy at this time.” This emphasizes why we consider Trend Model signals to be information flags, not action commands. Always check the chart.

Part of the reason Biotechs fell apart was the nomination of Robert F. Kennedy Jr. to the Health and Human Services department. He is known to be anti-COVID vaccines and just generally not a fan of chemicals for the body. This doesn’t necessarily bode well for this industry.

Participation has been plummeting as more and more stocks lose support at key moving averages. This drop below the 200-day EMA is perilous and given the negative indicators, the decline isn’t likely over yet. The PMO is dropping below the zero line on a Crossover SELL Signal and Stochastics are below 20 signaling extreme weakness. Support is arriving around 130.00, but it doesn’t look good.

The weekly chart shows the breakdown from the rising wedge formation, which is the normal resolution from this formation. The weekly PMO is tumbling lower. Support on the weekly chart is around 123.00. That would be a painful decline added to this already deep decline.

Introducing the new Scan Alert System!

Delivered to your email box at the end of the market day. You’ll get the results of our proprietary scans that Erin uses to pick her “Diamonds in the Rough” for the DecisionPoint Diamonds Report. Get all of the results and see which ones you like best! Only $29/month! Or, use our free trial to try it out for two weeks using coupon code: DPTRIAL2. Click HERE to subscribe NOW!

Learn more about DecisionPoint.com:

Watch the latest episode of the DecisionPointTrading Room on DP’s YouTube channel here!

Try us out for two weeks with a trial subscription!

Use coupon code: DPTRIAL2 Subscribe HERE!

Technical Analysis is a windsock, not a crystal ball. –Carl Swenlin

(c) Copyright 2024 DecisionPoint.com

Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional. Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.

DecisionPoint is not a registered investment advisor. Investment and trading decisions are solely your responsibility. DecisionPoint newsletters, blogs or website materials should NOT be interpreted as a recommendation or solicitation to buy or sell any security or to take any specific action.

Helpful DecisionPoint Links:

Trend Models

Price Momentum Oscillator (PMO)

On Balance Volume

Swenlin Trading Oscillators (STO-B and STO-V)

ITBM and ITVM

SCTR Ranking

Bear Market Rules

previous post
Democrats’ furor over ‘unqualified’ Trump nominees puts Biden’s staffing decisions back in the spotlight
next post
Are the Magnificent 7 Still the Kings of Wall Street?

Related Posts

S&P 500 Earnings 2024 Q3: Still Overvalued

January 10, 2025

The BEST Simple Moving Average Trading Strategy

February 5, 2025

5 Simple and Powerful Uses for Moving Averages

June 12, 2024

Disney Bust or Bargain? Here are the Levels...

August 20, 2024

Halloween Scare: The Stock Market Ends October on...

October 31, 2024

Top Ten Charts for August: Best Healthcare Stocks...

August 22, 2024

The SCTR Report: Why TSLA Stock Sees Tremendous...

September 5, 2024

Macro Market Outlook and Best Options Trade Ideas!

November 19, 2024

Why Stock Outperformance Might be ENDING!

September 11, 2024

S&P 500 Under Pressure, Can Strong Seasonality Save...

November 2, 2024

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Hawley opens probe into Meta after reports of AI romantic exchanges with minors

      August 15, 2025
    • Apple Watch getting redesigned blood oxygen feature following legal dispute

      August 15, 2025
    • From admiration to Alaska: A timeline of Trump and Putin’s high-stakes encounters

      August 15, 2025
    • Schumer claims Trump admin withholding Epstein files, threatens to sue

      August 15, 2025
    • The CEO in chief: How Trump is getting what he wants from big business

      August 15, 2025
    • American history won’t be displayed ‘in a woke manner’ at Smithsonian, Trump says

      August 15, 2025

    Categories

    • Business (1,348)
    • Politics (6,749)
    • Stocks (904)
    • World News (461)
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved